Open Market Insiders Trades
This list includes insiders general transaction with codes filed in Form 4 from SEC:
- P - Open market or private purchase of non-derivative or derivative security
- S - Open market or private sale of non-derivative or derivative security
- V - Transaction voluntarily reported earlier than required
| Ticker | Insider | Transaction Type | Ownership Type | Shares Traded | Value / Price | Filing Date |
|---|---|---|---|---|---|---|
|
SNPS
|
Brian M Beattie
EVP, Business Ops. & CAO |
SELL
Open market or private sale
|
Direct | 25,000 Reduced 65.69% |
$689,500
$27.58 p/Share
|
Mar 01
2011 |
|
NP
|
Sean T Erwin
Director |
SELL
Open market or private sale
|
Direct | 11,000 Reduced 100.0% |
$209,660
$19.06 p/Share
|
Mar 01
2011 |
|
ISR
|
Dwight William Babcock
CEO |
BUY
Open market or private purchase
|
Direct | 16,900 Added 10.03% |
$21,970
$1.3 p/Share
|
Feb 28
2011 |
|
PRSO
|
Sundari Mitra
Exec. VP of Engineering |
BUY
Open market or private purchase
|
Direct | 2,632 Added 3.77% |
$10,238
$3.89 p/Share
|
Feb 28
2011 |
|
PRSO
|
James Sullivan
Chief Financial Officer |
BUY
Open market or private purchase
|
Direct | 1,502 Added 18.77% |
$5,843
$3.89 p/Share
|
Feb 28
2011 |
|
SNPS
|
Chi Foon Chan
Co-CEO |
SELL
Open market or private sale
|
Direct | 50,000 Reduced 24.27% |
$1,392,500
$27.85 p/Share
|
Feb 28
2011 |
|
IOGPQ
|
Michael L Morrison
EVP & CFO |
SELL
Open market or private sale
|
Direct | 16,000 Reduced 49.96% |
$204,000
$12.75 p/Share
|
Feb 28
2011 |
|
IDIX
|
Ag Novartis |
BUY
Open market or private purchase
|
Indirect | 20,993 Added 0.01% |
$76,205
$3.63 p/Share
|
Feb 25
2011 |
|
IOGPQ
|
Nikolaos Bernitsas
SVP, GXT Imaging |
SELL
Open market or private sale
|
Direct | 15,037 Reduced 18.46% |
$188,865
$12.56 p/Share
|
Feb 25
2011 |
|
IOGPQ
|
Robert P Peebler
Executve Chairman |
SELL
Open market or private sale
|
Direct | 1,225,000 Reduced 59.33% |
$15,116,500
$12.34 p/Share
|
Feb 25
2011 |
|
ISR
|
Dwight William Babcock
CEO |
BUY
Open market or private purchase
|
Direct | 6,612 Added 4.68% |
$8,529
$1.29 p/Share
|
Feb 23
2011 |
|
FCNCA
|
Holding Frank B
> 10% Shareholder |
BUY
Open market or private purchase
|
Indirect | 40 Added 0.01% |
$8,099
$202.48 p/Share
|
Feb 22
2011 |
|
FCNCA
|
Holding Frank B
> 10% Shareholder |
BUY
Open market or private purchase
|
Indirect | 300 Added 0.05% |
$60,000
$200.0 p/Share
|
Feb 22
2011 |
|
IOGPQ
|
David L Roland
SVP-Gen Counsel & Corp Sec'y |
SELL
Open market or private sale
|
Direct | 40,000 Reduced 33.86% |
$492,400
$12.31 p/Share
|
Feb 22
2011 |
|
FCNCA
|
Holding Frank B Jr
Chairman and CEO |
BUY
Open market or private purchase
|
Indirect | 300 Added 1.51% |
$60,000
$200.0 p/Share
|
Feb 22
2011 |
|
ISR
|
Dwight William Babcock
CEO |
BUY
Open market or private purchase
|
Direct | 10,000 Added 4.86% |
$5,400
$0.54 p/Share
|
Feb 17
2011 |
|
EVR
|
Eduardo G Mestre
Vice Chairman |
SELL
Open market or private sale
|
Direct | 17,556 Reduced 7.5% |
$594,095
$33.84 p/Share
|
Feb 14
2011 |
|
BECN
|
David R Grace
CFO, Treasurer & EVP-Finance |
SELL
Open market or private sale
|
Direct | 13,741 Reduced 16.21% |
$298,729
$21.74 p/Share
|
Feb 11
2011 |
|
EVR
|
Adam B Frankel
General Counsel |
SELL
Open market or private sale
|
Direct | 4,000 Reduced 14.74% |
$135,080
$33.77 p/Share
|
Feb 11
2011 |
|
BECN
|
Robert R Buck |
SELL
Open market or private sale
|
Direct | 40,000 Reduced 37.62% |
$867,600
$21.69 p/Share
|
Feb 11
2011 |
|
EVR
|
Paul Pensa
Contr, Prin. Acct.Officer |
SELL
Open market or private sale
|
Direct | 370 Reduced 2.11% |
$12,502
$33.79 p/Share
|
Feb 11
2011 |
|
FCNCA
|
Holding Frank B
> 10% Shareholder |
BUY
Open market or private purchase
|
Indirect | 178 Added 0.48% |
$35,566
$199.81 p/Share
|
Feb 11
2011 |
|
BECN
|
Andrew R Logie
Director |
SELL
Open market or private sale
|
Direct | 138,015 Reduced 57.99% |
$3,017,008
$21.86 p/Share
|
Feb 10
2011 |
|
BECN
|
David R Grace
CFO, Treasurer & EVP-Finance |
SELL
Open market or private sale
|
Direct | 147,928 Reduced 63.57% |
$3,205,600
$21.67 p/Share
|
Feb 10
2011 |
|
FCNCA
|
Holding Frank B
> 10% Shareholder |
BUY
Open market or private purchase
|
Indirect | 1,544 Added 30.93% |
$306,561
$198.55 p/Share
|
Feb 10
2011 |
|
FCNCA
|
Holding Frank B
> 10% Shareholder |
BUY
Open market or private purchase
|
Indirect | 100 Added 0.27% |
$20,090
$200.9 p/Share
|
Feb 10
2011 |
|
EVR
|
Ralph Schlosstein
Co-CEO/Co-Chairman |
SELL
Open market or private sale
|
Direct | 6,567 Reduced 0.67% |
$227,350
$34.62 p/Share
|
Feb 09
2011 |
|
FCNCA
|
Holding Frank B
> 10% Shareholder |
BUY
Open market or private purchase
|
Indirect | 45 Added 0.01% |
$8,932
$198.5 p/Share
|
Feb 08
2011 |
|
FCNCA
|
Holding Frank B
> 10% Shareholder |
BUY
Open market or private purchase
|
Direct | 100 Added 1.64% |
$20,100
$201.0 p/Share
|
Feb 08
2011 |
|
EVR
|
Eduardo G Mestre
Vice Chairman |
SELL
Open market or private sale
|
Direct | 11,927 Reduced 4.55% |
$408,500
$34.25 p/Share
|
Feb 08
2011 |
|
NP
|
Sean T Erwin
Director |
SELL
Open market or private sale
|
Direct | 4,500 Reduced 100.0% |
$87,120
$19.36 p/Share
|
Feb 02
2011 |
|
NP
|
Sean T Erwin
Director |
SELL
Open market or private sale
|
Direct | 6,500 Reduced 100.0% |
$125,515
$19.31 p/Share
|
Feb 01
2011 |
|
MEI
|
Timothy Glandon
Vice President |
BUY
Open market or private purchase
|
Direct | 21 Added 0.02% |
$248
$11.79 p/Share
|
Jan 28
2011 |
|
ATRX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 74,500 Reduced 2.9% |
$85,675
$1.15 p/Share
|
Jan 26
2011 |
|
ATRX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 93,005 Reduced 3.49% |
$106,026
$1.14 p/Share
|
Jan 25
2011 |
|
AYI
|
Mark A Black
EVP |
SELL
Open market or private sale
|
Direct | 20,445 Reduced 34.39% |
$1,137,355
$55.63 p/Share
|
Jan 25
2011 |
|
ATRX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 72,800 Reduced 2.66% |
$86,632
$1.19 p/Share
|
Jan 24
2011 |
|
ATRX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 69,500 Reduced 2.48% |
$88,265
$1.27 p/Share
|
Jan 21
2011 |
|
ATRX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 5,700 Reduced 0.2% |
$8,436
$1.48 p/Share
|
Jan 20
2011 |
|
ATRX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 45,700 Reduced 1.6% |
$60,324
$1.32 p/Share
|
Jan 20
2011 |
|
ATRX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 42,800 Reduced 1.48% |
$65,912
$1.54 p/Share
|
Jan 19
2011 |
|
FCNCA
|
Holding Frank B
> 10% Shareholder |
BUY
Open market or private purchase
|
Indirect | 275 Added 2.69% |
$52,907
$192.39 p/Share
|
Jan 07
2011 |
|
NP
|
Sean T Erwin
Director |
SELL
Open market or private sale
|
Direct | 11,000 Reduced 100.0% |
$217,800
$19.8 p/Share
|
Jan 03
2011 |
|
FCNCA
|
Holding Frank B
> 10% Shareholder |
BUY
Open market or private purchase
|
Indirect | 300 Added 9.62% |
$59,010
$196.7 p/Share
|
Dec 31
2010 |
|
FCNCA
|
Irrevocable Trust Under Agreement Dated March 28 1990
> 10% Shareholder |
BUY
Open market or private purchase
|
Direct | 200 Added 0.07% |
$39,612
$198.06 p/Share
|
Dec 23
2010 |
|
FCNCA
|
Holding Frank B
> 10% Shareholder |
BUY
Open market or private purchase
|
Indirect | 240 Added 8.7% |
$45,600
$190.0 p/Share
|
Dec 22
2010 |
|
SNPS
|
Aart De Geus
EXECUTIVE CHAIR |
SELL
Open market or private sale
|
Direct | 58,981 Reduced 10.89% |
$1,607,232
$27.25 p/Share
|
Dec 21
2010 |
|
KWR
|
L Wilbert Platzer
SVP, Global Ops, EHS & Prcmt |
SELL
Open market or private sale
|
Direct | 6,549 Reduced 21.57% |
$288,156
$44.0 p/Share
|
Dec 21
2010 |
|
KWR
|
Ronald J Naples
Director |
SELL
Open market or private sale
|
Direct | 10,000 Reduced 10.0% |
$430,000
$43.0 p/Share
|
Dec 20
2010 |
|
FCNCA
|
Holding Frank B
> 10% Shareholder |
BUY
Open market or private purchase
|
Indirect | 33 Added 1.43% |
$6,250
$189.4 p/Share
|
Dec 20
2010 |